N/A N=168 Comparison of 2 Different Resin Based Filling Materials in Posterior Teeth - a Multicenter Study
Caries · Unsatisfactory or Defective Restoration of Tooth
Primary: Score for Surface Luster — 1.89; 1.62 scores on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=250 Promoting Recovery Optimization With WALKing Exercise After Stroke
Stroke
Primary: Steps Per Day — 1307; 406; 1542 steps per day
N/A N=20 The Use of a Consumer-Based mHealth Dietary App and Health Coaching With Kidney Transplant Recipients
Kidney Transplant · Kidney Transplant; Complications
Primary: The Feasibility of the Study Recruitment for the Study — 20 Participants
Phase 2 N=104 Safety, Tolerability and Prophylactic Antiviral Activity of Neumifil Against Influenza Via a Human Viral Challenge Model
Influenza Viral Infections
Primary: Incidence of Symptomatic Influenza Infection — 6; 6; 16; 12 Participants — p=0.0331
Phase 1 N=34 A Study of LY3022855 In Participants With Breast or Prostate Cancer
Neoplasms · Neoplasm Metastasis
Primary: Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets — -10.31; 5.12; -16.39; -26.76 Percent Change
Phase 4 N=175 Amlodipine Versus Nifedipine ER for the Management of Postpartum Hypertension
Hypertension in Pregnancy
Primary: Length of Stay — 73.5; 72.0 hours
N/A N=88 An Integrated-Delivery-of-Care Approach to Improve Patient Outcomes, Safety, Well-Being After Orthopaedic Trauma
Musculoskeletal Injury Trauma
Primary: Change From Baseline, at Weeks 2, 6 and 12 on the Patient Reported Outcome Measurement Information System (PROMIS) - Physical Function Between the Groups. — 18.65; 17.6…
Phase 3 N=18 Study to Evaluate Patients With Cerebrotendinous Xanthomatosis (RESTORE)
CTX
Primary: Change From Baseline in Urine 23S-Pentol During the Two Double-Blind Periods — 7.18; 6.96; 7.45; 10.34 natural log of ng/mL — p=<0.0001
Phase 1 N=54 A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma
Melanoma and Metastatic Colorectal Cancer
Primary: Number of Participants With Dose-Limiting Toxicity (DLT) During Dose Escalation Phase — 0; 1; 0; 0 Participants
Phase 1 N=12 A Study to Learn About the Study Medicine Called Nirmatrelvir/Ritonavir in People Who Are Healthy Volunteers Co-administered the Medicine Rosuvastatin
Pharmacokinetics · Healthy Volunteers
Primary: Area Under the Concentration-Time Curve From Time Zero (0) Extrapolated to Infinity (AUCinf) of Rosuvastatin in Period 1 and 2 — 58.62; 72.78 Nanogram*hour per milliliter
Phase 3 N=602 PREPARE (A5361s) Ancillary Study of REPRIEVE (A5332)
HIV-1 Infection
Primary: Physical Function: Rate of Change in Chair Rise Rate — -0.035; 0.07 rises/minute per year — p=0.31
Phase 3 N=152 An Extension Study to Assess Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-4)
Schizophrenia
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 36; 45 Participants
Phase 4 N=519 Acetazolamide in Decompensated Heart Failure With Volume OveRload (ADVOR)
Acute Decompensated Heart Failure · Volume Overload
Primary: Successful Decongestion — 79; 108 Participants
Phase 3 N=207 Research Study Looking at How Well Semaglutide Works in People Living With Obesity and Prediabetes
Obesity
Primary: Change in Body Weight (Percentage [%]) — -14.4; -2.7 Percentage (%) of body weight — p=<0.0001
N/A N=23 Endocrine, Metabolic and Microbiome Influence on the Post-acute Sequelae SARS-CoV-2 (PASC)
Covid19
Primary: Insulin-Like Growth Factor-1 (IGF1) — 142.8; 137.6 ng/ml